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Abstract
Transgenic plants are a novel way to produce and deliver oral vaccines. Arabidopsis thaliana material shown previously to express the
tuberculosis (TB) antigen ESAT-6 fused to the B subunit of Escherichia coli heat-labile enterotoxin (LTB) was fed to mice and the resulting
immune response investigated. The plant-made LTB-ESAT-6 fusion protein induced antigen-specific responses fromCD4+ cells and increased
IFN-! production, indicating a Th1 response. In addition, a Th2 response was induced in the Peyer’s patch. This is the first report of an orally
delivered, subunit, tuberculosis vaccine priming an antigen-specific, Th1 response.
© 2005 Elsevier Ltd. All rights reserved.
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1. Introduction
Tuberculosis (TB) is the leading infectious disease in the
developing world. In humans, TB is primarily caused by
Mycobacterium tuberculosis. Since the portal of entry and
primary site of infection ofM. tuberculosis is the respiratory
track, mucosal vaccination should have inherent advantage to
inducing a protective immune response. Unfortunately, par-
enteral immunization, the traditional means of vaccine deliv-
ery, is a poor inducer of mucosal immunity. Mucosal delivery
is the best way to induce a mucosal immune response. It has
the added advantage of not needing needle administration,
thereby cutting cost and increasing ease of vaccination. It
has been suggested that transgenic plants expressing ther-
apeutic proteins are ideal vehicles to produce and orally
deliver protective antigens. It has been speculated that the
plant cell wall delays digestion of plant-made and deliv-
ered antigen; thus, more antigen is taken up and presented
to the gut associated lyphoid tissue [1]. The purpose of this
study was to investigate the ability of transgenic plants to
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serve as a novel delivery system for an oral tuberculosis vac-
cine. We have previously produced transgenic Arabidopsis
thaliana plants expressing the immuno-dominant TB anti-
gen ESAT-6 (early secretory antigenic target, 6 kDa) fused to
the B subunit of the Escherichia coli heat-labile enterotoxin
(LTB) [2]. In the present study, we tested the oral immuno-
genicity of the plant-made, subunit vaccine in mouse feed
trials.
2. Materials and methods
2.1. Animals
Specific pathogen free female, C57BL/6 mice were pur-
chased from Charles River Laboratories (Wilmington, MA)
at 8–10 weeks of age and kept under SPF conditions at
the Laboratory Animal Resources Facility and Bioenviron-
mental Hazard Research Building at Colorado State Uni-
versity. The mice were housed in isolator cages (Thoren
Caging Systems Inc., PA) to which air is supplied directly
and then exhausted. Four mice were housed per cage.
Upon arrival, mice were rested 1 week before the start of
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Table 1
Summary of treatments performed in the mice challenge trials
Group Treatment Animal number
1 Unvaccinated mice 5
2 Fed, wildtype plant 5
3 Fed wildtype plant plus saponin 5
4 Fed, transgenic plant 5
5 Fed transgenic plant plus saponin 5
6 Oral BCG 5
the experiment. When not being fed test treatments, the
mice had free access to sterile water and standard mouse
chow. Mice were monitored on a daily basis for signs of
weight loss and condition. Each treatment contained five
mice.
2.2. Vaccination
The treatments are summarized in Table 1. For feed immu-
nizations, test animals were transferred to individual cages
and fasted for 8 h before introduction of the test diet. The
mice had continuous supply of water. The test diet remained
with the animals for 16 h and consisted of powdered, freeze-
dried plant cells mixed with apple cider in a ratio of 1:3,
respectively (w/v). In treatments using saponin, 10mg of
food grade Quillaja extract powder (Garuda) were added
per gram of plant material. Test animals were provided with
3 g of the mix (92.6!g of plant-made LTB-ESAT-6). Feed
treatments were given on days 0, 7, 14 and 28. The Bacil-
lus Calmette-Gue´rin (BCG) vaccine was used as a positive
control. Mice were orally vaccinated by initially receiving
100!l of 3% (w/v) sodium bicarbonate prepared in sterile,
pyrogen-free water (Abbott Labs, IL) before 100!l BCG at
1× 108 colony forming units (CFU) per milliliter. The BCG
suspensionwas administered via oral gavage on days 0, 14, 28
and 42.
2.3. Mouse challenge model
Mice were challenged as per the NIH standard TB chal-
lenge short protocol.M. tuberculosis strain H37Rv (Trudeau
Mycobacterial Culture Collection-TMCC #102) was grown
to mid-log phase in Proskauer–Beck medium containing
0.01% Tween-80 and stored at−80 ◦C. Three weeks follow-
ing the last immunization, mice were infected via the aerosol
route using a Glas-Col aerosol generator (Glas-Col, Terre
Haute, IN), such that ∼100 viable bacteria were deposited
in the lungs of each animal. After 50 days, animals were
sacrificed by carbon dioxide asphyxiation, as approved by
the CSU Animal Care and Use Committee. The number
of viable bacteria in the lungs and spleen was determined
at specific time points. Serial dilutions of individual par-
tial organ homogenates were plated on nutrient Middlebrook
7H11 agar, and counting bacterial colonies after 21 days of
incubation at 37 ◦C.
2.4. Isolation and characterization of pulmonary, lymph
node and spleen cells
Lungs from each mouse were perfused through the
heart with 10ml cold PBS containing 3U/ml heparin
(Sigma–Aldrich, St. Louis, MO). The lungs were removed
from the pulmonary cavity and placed in cold Dulbecco’s
minimal essential medium (DMEM; Cellgro, Herndon, VA).
The tissue was then disrupted using sterile razor blades and
incubated for 30min at 37 ◦C in a final volume of 2ml
DMEM containing 0.7mg/ml collagenase D (Roche Applied
Science, Indianapolis, IN) and 30!g/ml deoxyribonuclease
(Sigma–Aldrich). Following incubation, the digested lung
tissuewas gently passed through a sterile 70!mnylon screen.
The cells were rinsed using 8ml cold DMEM supplemented
with 10% heat-inactivated endotoxin low fetal calf serum
(Atlas Biologicals, Fort Collins, CO), 10mM HEPES buffer
(Sigma–Aldrich), 2mM l-glutamine (Sigma–Aldrich), 2%
MEM-non-essential amino acids (100×; Sigma–Aldrich),
50!M 2-mercaptoethanol (Sigma–Aldrich) and centrifuged
at 200× g. Spleens and lymph nodes were also passed
through a wire screen to prepare single-cell suspensions. Red
blood cells were lysed using Gey’s solution (0.15M NH4Cl,
10mMKHCO3) and the sampleswere centrifuged and resus-
pended in DMEMplus supplements. A cell aliquot from each
mousewas counted using a hemacytometer and aliquots were
taken for flow cytometric analysis. Viable cells were enumer-
ated by trypan blue exclusion.
2.5. Preparation of leukocytes for flow cytometric
analysis
Counted cells were centrifuged for 5min, 1200 rpm, at
4 ◦C, resuspended in 200!l PBS with 0.05% sodium azide
and incubated on ice for 15–30min. Cells were pelleted
by centrifugation and resuspended. Twenty-five microliters
of fluorochrome labeled antibodies against appropriate sur-
face markers were added to appropriate wells, and the plates
incubated on ice. All antibodies were purchased from BD
PharMingen (San Diego, CA). Cells were incubated in the
dark for 20min at 4 ◦C with specific antibody (directly con-
jugated to fluorescein isothiocyanate [FITC], phycoerythrin
[PE], peridinin chlorophyll a protein [PerCP], or allophyco-
cyanin [APC] at 3!g/ml), followed by two washes using
PBS with sodium azide. For T cell analysis, cells were
washed twice and incubated separately with an equal vol-
ume of cRPMI containing Monensin (10ml cRPMI, 30!l
Monensin, [40!l anti-CD28, 4!l anti-CD3]) at 37 ◦C, 90%
humidity, 5% CO2 for 4 h. Cells were washed twice, cen-
trifuged and divided into two wells on 96-well plates before
being washed and centrifuged. Surface staining antibod-
ies were added and the plate incubated at 4 ◦C in the
dark for 30min. The cells were washed twice then incu-
bated with CytofixTM Buffer (BD Biosciences, Cat. No.
2014KZ) at 4 ◦Cfor 30min.The cellswerewashed twicewith
200!l 1×Perm/WashTM Buffer (BD Biosciences, Cat. No.
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2091KZ) then resuspended in 200!l Perm/WashTM Buffer
before centrifugation and addition of intracellular staining
antibodies. The plates were incubated at 4 ◦C in the dark for
30min before washing twice. Two hundred microliters of
Ab-stained cells were analyzed in a FACSCaliber (BD Bio-
sciences).
2.6. Flow cytometric analysis
Cell-surface markers were analyzed with the following
specific antibodies: FITC-CD44 (clone IM7), CD3" (clone
145-2C11), CD62L (clone MEL-14), PerCP-CD8# (clone
53-6.7), CD4 (clone RM4-5), APC-CD3 (clone 145-2C11),
CD127 (clone A7R34). For intracellular antibody staining,
a single-cell suspension was prepared as described above
and the cells were resuspended in DMEM with supplements
and stimulated with 0.1!g/ml anti-CD3" (clone 145-2C11),
1!g/ml anti-CD28 (clone 37.51), in the presence of 3!M
Monensin for 4 h at 37 ◦C, 5% CO2. Cells were stained with
antibodies for cell-surface molecules as described above,
before permeabilization with BD Cytoperm/Cytofix (BD
PharMingen, San Diego, CA) according to the manufac-
turer’s instructions. Cells were incubated with FITC anti-
IFN-$ (clone XMG1.2) for 20min at 4 ◦C, washed twice,
and resuspended in PBS with sodium azide before analysis.
Appropriate isotype controls were prepared simultaneously
and were included in each analysis.
The FACSCaliber is calibrated weekly through analysis of
single-stained beads (FITC, PE, PerCP, APC and unstained)
in conjunction with the FACSComp program to determine
the sensitivity of the PMTs and to set the time delay between
the 488 and 635 lasers. In addition, unstained and single-
stained cells were prepared and run with each experimental
time-point to determine the correct compensation values to
eliminate spectral overlap.
3. Results
The amount of test diet eaten by each mouse varied with
the individual; however, the majority of mice consumed
above 75% of the diet. After pulsing with ESAT-6, cells from
mice inoculated with the plant-made LTB-ESAT-6 fusion
had significantly (ANOVA, α= 0.05) more CD4+ lympho-
cyte proliferation in the mesenteric lymph nodes than other
treatments (Fig. 1b). No significant difference could be deter-
mined between the treatments with CD4+ cells in the Peyer’s
patches (Fig. 1a) orCD8+cells in thePeyer’s patches (Fig. 1c)
or mesenteric lymph nodes (Fig. 1d). There was, however, a
trend for the transgenic plant material treatments and BCG
treatment in the Peyer’s patches to have higher CD8+ cell
proliferation (Fig. 1c). Mice inoculated with the plant-made
LTB-ESAT-6 fusion with adjuvant and oral BCG had sig-
nificantly more CD4+ cells producing IL-10 in the Peyer’s
patches (ANOVA, α= 0.05) (Fig. 2a) while mice inoculated
with the plant-made LTB-ESAT-6 fusion without adjuvant
had significantly more CD4+ cells producing IFN-$ than any
other treatment (Fig. 2b). There was no significant differ-
Fig. 1. Proliferation of lymphocytes in Peyer’s patches (a) and (c) and mesenteric lymph nodes (b) and (d) taken from animals prior challenge. Blc/6 mice were
vaccinated on days 0, 7, 14 and 28. Where control plants were wildtype, plant feed treatments, and trans plant represents transgenic plants feed treatments.
Symbols indicate a significantly different result (α= 0.05). The bars represent the average of five samples and the error bars the standard deviation of the means.
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Fig. 2. Percentage of lymphocytes producing cytokines in the Peyer’s patches (a) and mesenteric lymph nodes (b) taken from animals prior challenge. Blc/6
mice were vaccinated on days 0, 7, 14 and 28.Where control plants were wildtype, plant feed treatments; trans plant represents transgenic plants feed treatments.
IFN-!: interferon gamma; IL-10: interleukin 10. Symbols indicate a significantly different result (α= 0.05). Bars with the same symbols are not significantly
different. The bars represent the average of five samples and the error bars the standard deviation of the means.
ence between IL-10 producing CD4+ cells in the transgenic
plant plus adjuvant and oral BCG treatments in the Peyer’s
patches (Fig. 2a); any treatment with regards to IFN-! in the
Peyer’s patches (Fig. 2a); or IL-10 production in the mesen-
teric lymph nodes (Fig. 2b). No difference was seen between
treatments concerning cytokine production by CD8+ cells
(data not shown). We observed significant induction of IFN-
! by the transgenic plant treatment in the mesenteric lymph
nodes and evidence of ESAT-6 specific CD8+ cell prolif-
eration in the Peyer’s patches. However, despite oral BCG
treated mice having a one log drop in colony forming units
in the lung and spleen, no protection was given by the trans-
genic plant treatments (with or without saponin) when mice
were challenged with M. tuberculosis (H37Rv strain) (data
not shown).
4. Discussion
An effective response against M. tuberculosis involves
a complex interaction of a range of immune compo-
nents. Since M. tuberculosis is an intracellular pathogen, a
strong cell-mediated immune (CMI) response assisted by a
humoral response is needed to control infection. The CMI
response involves CD4+ and CD8+ T cells, macrophages
and cytokines including IFN-!, IL-12, TNF-" and IL-6 [3].
Many preliminary TB vaccine studies look for induction of
subsets of these components, particularly IFN-!; however,
the best known way to find resistance afforded by a new TB
vaccine is to challenge the vaccinated animals with virulent
Mtb, preferably by inhaling a low dose of bacteria [4].
Oral delivery of a plant-made vaccine based on the model
tuberculosis antigen ESAT-6 stimulated CD4+ cells to pro-
duce IFN-! and therefore induced a Th1 response in the
mesenteric lymph nodes. This is the first report of a plant-
made vaccine inducing an immune response to a tuberculo-
sis antigen and of an orally delivered, subunit, tuberculosis
vaccine priming a Th1 response. Crude saponin was used
as an adjuvant since it has been found to stimulate mixed
immune responses skewed toward a Th1 response [5,6]. In
this study, the plant-made, LTB-ESAT-6 fusion adjuvanted
with saponins stimulated CD4+ cells to produce IL-10 in the
Peyer’s patches. Production of IL-10 could be indicative of a
Th2 response or oral tolerance [7]; unfortunately, the studies
required to determine if oral tolerancewas induced, for exam-
ple analysis of TGF-# production, was not performed. ESAT-
6 is a major target molecule for IFN-! producing Th1 cells in
the murine model of TB infection [5]; but fusion to the LTB
carrier protein may have changed the way in which ESAT-6
was taken up and detected by themucosal immune system [8].
There is considerable evidence that the ganglioside binding
by LTB plays an important role in the signal transduction
pathways inducing cellular immunomodulation, prolifera-
tion, differentiation, transformation and suppression. Crude
saponin has been suggested to amplify the immune response
and not modulate it [9]. Since the LTB used in this exper-
iment primarily induces a Th2 response, we believe CD4+
cell production of IL-10 results from saponins amplifying an
ESAT-6 specific Th2 response in the Peyer’s patches because
of different signal transduction pathways triggered by fusion
to LTB. Hence, in the current fusion format, the delivery of
the test diet with saponin held no advantage. It merely ampli-
fied and undesired type of immune response.
Since the efferent lymphatics of the Peyer’s patches’ drain
to the mesenteric lymph nodes [10], it was interesting to see
a Th2 response by CD4+ cells in the inductor site (Peyer’s
patches), but a Th1 response by CD4+ cells in the secondary
site of the mesenteric lymph nodes. We believe the LTB-
ESAT-6 fusion induced CD4+ cells to help produce a local,
antigen-specific immune response in the enriched source of
IgA committed plasma precursor cells found in the Peyer’s
patches [11]; however, upon entering the different microenvi-
ronment of the mesenteric lymph nodes, an antigen-specific
Th1 immune response was induced.
Oral delivery of a plant-made LTB-ESAT-6 fusion pro-
tein induced promising responses (antigen-specific responses
fromCD4+ cells; IFN-! production; equivalent CD8+ prolif-
eration to BCG). However, as previously found, production
of IFN-! did not correlate with ability to reduce bacterial load
[12] and the mice were not protected against challenge with
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M. tuberculosis. Given the encouraging data from our initial
attempts to produce a plant-made vaccine against tuberculo-
sis, we are currently making new constructs using a different
targeting system. The long-term goal of this novel approach
for vaccination is to provide a flexible, tuberculosis vaccine
that is safe and effective for naı¨ve or BCG immunized chil-
dren, adults and animals.
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